Monday, 28 April, 2025

​Craif Secures $22M to Advance Non-Invasive Urine-Based Cancer Detection Platform​

Japanese startup Craif has raised $22 million in Series C funding to expand its AI-powered early cancer detection platform, miSignal, into the U.S. market. The test uses urinary microRNA biomarkers to identify early-stage cancers, offering a non-invasive alternative to traditional screenings. Currently available in Japan through clinics and pharmacies, Craif aims to make early cancer detection more accessible and convenient.